Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
07:00am, Monday, 16'th Jun 2025
Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
04:01pm, Thursday, 05'th Jun 2025
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Bioph
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
07:30am, Thursday, 29'th May 2025
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimet
Crescent Biopharma Appoints David Lubner to Board of Directors
07:30am, Monday, 28'th Apr 2025
Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology
Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
11:20am, Wednesday, 05'th Mar 2025
NEW YORK , March 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
08:00am, Wednesday, 26'th Feb 2025
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 b
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
08:00am, Tuesday, 12'th Nov 2024
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, In
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC
06:46pm, Tuesday, 05'th Nov 2024
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. - GLYC
03:49pm, Sunday, 03'rd Nov 2024
NEW YORK , Nov. 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securi
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimet
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders
11:51am, Tuesday, 29'th Oct 2024
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating GlycoMimetics (NASDAQ: GLYC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crescent. Click here to
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders
11:47am, Tuesday, 29'th Oct 2024
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders
08:22am, Tuesday, 29'th Oct 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of GlycoMimetics, Inc. (NASDAQ: GLYC) and Crescent Biopharma, Inc. is fair to GlycoMimetic
